SAN DIEGO, Feb. 13 /PRNewswire/ -- AndroScience Corporation, a privately held biotech company, has successfully filed an IND for acne indication and will proceed with Human Clinical Trials in the first quarter of 2007. AndroScience has developed its lead compound ASC-J9, a novel anti-androgen that enhances androgen receptor degradation, into a topical cream for acne treatment that will be tested in the clinical trials.
Prior to this clinical stage, AndroScience won the Third Place Award (out of >900 posters) for its presentation entitled "Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris" at the Annual Meeting of American Academy of Dermatology in March of 2006; and in July 2006, AndroScience was awarded a Phase II SBIR grant ($800,000) from the NIH to develop ASC-J9 for acne treatment.
AndroScience also has drug candidates in preclinical testing for the treatment of alopecia, prostate cancer, benign prostate hyperplasia (BPH) and other androgen related disorders. AndroScience intends to build up corporate value by developing its proprietary compounds through preclinical and clinical development to registration and commercialization.
Charles C-Y Shih, Ph.D.
CONTACT: Charles C-Y Shih, Ph.D., of AndroScience Corporation,+1-858-638-7230